TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE NORTH AMERICA SJS/TEN TREATMENT MARKET 84
1.4 LIMITATIONS 87
1.5 MARKETS COVERED 87
2 MARKET SEGMENTATION 92
2.1 MARKETS COVERED 92
2.2 GEOGRAPHICAL SCOPE 93
2.3 YEARS CONSIDERED FOR THE STUDY 94
2.4 CURRENCY AND PRICING 94
2.5 DBMR TRIPOD DATA VALIDATION MODEL 95
2.6 MULTIVARIATE MODELLING 98
2.7 TREATMENT LIFELINE CURVE 98
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 99
2.9 DBMR MARKET POSITION GRID 100
2.10 MARKET APPLICATION COVERAGE GRID 101
2.11 VENDOR SHARE ANALYSIS 102
2.12 SECONDARY SOURCES 103
2.13 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHTS 107
4.1 KEY TRENDS 108
4.2 COST OF TREATMENT 109
4.3 KEY PLAYERS STRATEGIES 110
4.4 LONG TERM GROWTH APPROACH 111
5 EPIDEMIOLOGY 112
6 INDUSTRY INSIGHTS 116
6.1 PATENT ANALYSIS 116
6.2 DEMOGRAPHIC TRENDS 118
6.3 PATIENT FLOW DIAGRAM 119
6.4 KEY PRICING STRATEGIES 120
6.5 KEY PATIENT ENROLLMENT STRATEGIES 120
7 MARKET OVERVIEW 123
7.1 DRIVERS 125
7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN 125
7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT 126
7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN 126
7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT 127
7.2 RESTRAINTS 129
7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN 129
7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT 129
7.3 OPPORTUNITIES 130
7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN 130
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT 131
7.4 CHALLENGES 131
7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN 131
7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT 132
8 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY TREATMENT 133
8.1 OVERVIEW 134
8.2 MEDICATIONS 137
8.2.1 ANTIHISTAMINES 138
8.2.1.1 HYDROXYZINE 138
8.2.1.2 FEXOFENADINE 138
8.2.2 CORTICOSTEROID 139
8.2.2.1 DEXAMETHASONE 139
8.2.2.2 PREDNISOLONE 139
8.2.2.3 METHYLPREDNISOLONE 139
8.2.2.4 HYDROCORTISONE 139
8.2.2.5 OTHERS 139
8.2.3 ANTIBIOTICS 139
8.2.3.1 NAFCILLIN 140
8.2.3.2 GENTAMICIN 140
8.2.3.3 OTHERS 140
8.2.4 ANALGESICS 140
8.2.4.1 MORPHINE 140
8.2.4.2 FENTANYL CITRATE 141
8.2.4.3 OTHERS 141
8.2.5 ANTICOAGULANTS 141
8.2.6 ANTISEPTICS 141
8.2.6.1 CHLORHEXIDINE GLUCONATE 141
8.2.6.1.1 PERIOGARD 142
8.2.6.1.2 PERIDEX 142
8.2.6.1.3 AVAGARD 142
8.2.6.1.4 HIBICLENS 142
8.2.6.1.5 OTHERS 142
8.2.6.2 OCTENISEPT 142
8.2.6.3 POLYHEXANIDE SOLUTIONS 142
8.2.6.4 OTHERS 143
8.2.7 INTRAVENOUS IMMUNOGLOBULIN 143
8.2.8 CYCLOSPORINE 143
8.2.8.1 NEORAL 143
8.2.8.2 SANDIMMUNE 143
8.2.8.3 OTHERS 143
8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-)BLOCKING AGENT (ETANERCEPT) 143
8.2.10 OTHER TREATMENT 144
8.2.10.1 CYCLOPHOSPHAMIDE 144
8.2.10.2 N-ACETYLCYSTEINE 144
8.2.10.3 MONOCLONAL ANTIBODIES 144
8.2.10.4 THALIDOMIDE 144
8.3 SUPPORT CARE 144
8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES 145
8.3.2 PAIN MANAGEMENT 146
8.3.2.1 LIDOCAINE 146
8.3.2.2 OTHERS 146
8.3.3 NUTRITION SUPPORT 146
8.3.4 ORAL CARE 146
8.3.5 PLASMAPHERESIS 146
8.3.6 BANDAGES 146
8.3.6.1 BIOLOGICAL DRESSING 147
8.3.6.1.1 ALLOGRAFT 147
8.3.6.1.2 XENOGRAFT 147
8.3.6.1.3 HOMOGRAFT 147
8.3.6.1.4 OTHERS 147
8.3.6.2 BIOSYNTHETIC DRESSING 148
8.3.6.3 SILVER IMPREGNATED DRESSING 148
8.4 HOSPITALIZATION 148
8.5 ISOLATION 149
8.6 OINTMENTS 149
8.6.1 BENZOCAINE 150
8.6.2 AMERICAINE 150
8.6.3 ANBESOL 150
8.6.4 CHIGGEREX PLUS 150
8.6.5 OTHERS 151
8.7 OTHERS 151
9 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS 152
9.1 OVERVIEW 153
9.2 PHYSICAL EXAM 156
9.3 SKIN BIOPSY 156
9.4 MEDICAL HISTORY 157
9.5 BLOOD TEST 158
9.5.1 COMPLETE BLOOD COUNT 159
9.5.2 ERYTHROCYTE SEDIMENTATION RATE 159
9.5.3 COAGULATION STUDIES 159
9.5.4 UREA AND ELECTROLYTES 160
9.5.5 LIVER FUNCTION TEST 160
9.6 CULTURES 160
9.7 OTHERS 161
10 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY CAUSE 162
10.1 OVERVIEW 163
10.2 SPECIFIC TREATMENT 166
10.3 INFECTION 166
10.4 OTHERS 167
11 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 168
11.1 OVERVIEW 169
11.2 ORAL 172
11.3 PARENTERAL 172
11.3.1 INTRAVENOUS 173
11.3.2 SUBCUTANEOUS 173
11.3.3 OTHERS 173
11.4 TOPICAL 173
11.4.1 OINTMENTS 174
11.4.2 SOLUTION 174
11.4.3 CREAMS 175
11.4.4 OTHERS 175
11.5 OTHERS 175
12 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE 176
12.1 OVERVIEW 177
12.2 BRANDED 180
12.2.1 NEORAL 181
12.2.2 SANDIMMUNE 181
12.2.3 VISTARIL 181
12.2.4 DURAMORPH 181
12.2.5 FENTORA 181
12.2.6 ENBREL 181
12.2.7 OTHERS 181
12.3 GENERIC 181
13 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY THERAPY TYPE 183
13.1 OVERVIEW 184
13.2 COMBINATION THERAPY 187
13.3 MONOTHERAPY 187
14 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE 189
14.1 OVERVIEW 190
14.2 GERIATRIC 193
14.2.1 FEMALE 194
14.2.2 MALE 194
14.3 ADULT 194
14.3.1 FEMALE 195
14.3.2 MALE 195
14.4 PEDIATRIC 195
15 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY END USER 197
15.1 OVERVIEW 198
15.2 HOSPITALS 201
15.3 SPECIALTY CLINICS 201
15.4 AMBULATORY SURGICAL CENTER 202
15.5 HOMECARE SETTING 203
15.6 OTHERS 203
16 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL 205
16.1 OVERVIEW 206
16.2 RETAIL PHARMACIES 209
16.2.1 HOSPITAL ASSOCIATED PHARMACIES 210
16.2.2 DRUG STORE 210
16.2.3 ONLINE PHARMACIES 210
16.3 DIRECT TENDERS 210
16.4 OTHERS 211
17 NORTH AMERICA SJS/TEN TREATMENT MARKET, BY REGION 212
17.1 NORTH AMERICA 213
17.1.1 U.S. 227
17.1.2 CANADA 235
17.1.3 MEXICO 244
18 NORTH AMERICA SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE 253
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 253
19 SWOT ANALYSIS 254
20 COMPANY PROFILE 255
20.1 PFIZER INC. 255
20.1.1 COMPANY SNAPSHOT 255
20.1.2 REVENUE ANALYSIS 255
20.1.3 COMPANY SHARE ANALYSIS 256
20.1.4 PRODUCT PORTFOLIO 256
20.1.5 RECENT DEVELOPMENT 256
20.2 NOVARTIS AG 257
20.2.1 COMPANY SNAPSHOT 257
20.2.2 REVENUE ANALYSIS 257
20.2.3 COMPANY SHARE ANALYSIS 258
20.2.4 PRODUCT PORTFOLIO 258
20.2.5 RECENT DEVELOPMENT 258
20.3 MERCK & CO., INC. 259
20.3.1 COMPANY SNAPSHOT 259
20.3.2 REVENUE ANALYSIS 259
20.3.3 COMPANY SHARE ANALYSIS 260
20.3.4 PRODUCT PORTFOLIO 260
20.3.5 RECENT DEVELOPMENT 260
20.4 AMNEAL PHARMACEUTICAL LLC. 261
20.4.1 COMPANY SNAPSHOT 261
20.4.2 REVENUE ANALYSIS 261
20.4.3 COMPANY SHARE ANALYSIS 262
20.4.4 PRODUCT PORTFOLIO 262
20.4.5 RECENT DEVELOPMENT 262
20.5 AMGEN INC. 263
20.5.1 COMPANY SNAPSHOT 263
20.5.2 REVENUE ANALYSIS 263
20.5.3 PRODUCT PORTFOLIO 264
20.5.4 RECENT DEVELOPMENT 264
20.6 ADVACARE PHARMA 265
20.6.1 COMPANY SNAPSHOT 265
20.6.2 PRODUCT PORTFOLIO 265
20.6.3 RECENT DEVELOPMENT 265
20.7 BD 266
20.7.1 COMPANY SNAPSHOT 266
20.7.2 REVENUE ANALYSIS 266
20.7.3 PRODUCT PORTFOLIO 267
20.7.4 RECENT DEVELOPMENT 267
20.8 CARDINAL HEALTH 268
20.8.1 COMPANY SNAPSHOT 268
20.8.2 REVENUE ANALYSIS 268
20.8.3 PRODUCT PORTFOLIO 269
20.8.4 RECENT DEVELOPMENT 269
20.9 COLGATE-PALMOLIVE COMPANY 270
20.9.1 COMPANY SNAPSHOT 270
20.9.2 REVENUE ANALYSIS 270
20.9.3 PRODUCT PORTFOLIO 271
20.9.4 RECENT DEVELOPMENT 271
20.10 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA) 272
20.10.1 COMPANY SNAPSHOT 272
20.10.2 REVENUE ANALYSIS 272
20.10.3 PRODUCT PORTFOLIO 273
20.10.4 RECENT DEVELOPMENT 273
20.11 ICPA HEALTH PRODUCTS LTD 274
20.11.1 COMPANY SNAPSHOT 274
20.11.2 PRODUCT PORTFOLIO 274
20.11.3 RECENT DEVELOPMENT 274

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.